ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Income Before Tax

Profit after all operating and non-operating items but before income tax.

ImmunityBio, Inc.NASDAQ: IBRX

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax remains negative

Q3 FY2026 income before tax was -$184.57M, compared with -$67.31M a year earlier. Trailing-twelve-month income before tax was -$1.11B.

Context

  • Income before tax amounted to 310.4% of revenue in FY2025, down 2495.0 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$184.57M or moves back toward the trailing-twelve-month quarterly average of -$277.46M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$184.57M+19.9% QoQ
Last fiscal yearDec 2025
-$351.61M+15.0% YoY
LTMSep 2026
-$1.11B-218.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-174.2%——
1 year+15.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(351.61M) USD
Year-over-year change
+15.0%

Income Before Tax vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -218.3% is the 9th highest of 11, against a peer median of +27.3%.
  • Income before tax amounts to 607.9% of revenue for IBRX, versus a peer median of 60.2%.
IBRX Competitors
Income Before Tax for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$32.2M USD+114.5%—2.4%
IMCRImmunocore Holdings plcLTM Mar 2026-$7.82M USD+65.7%—2.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$9.44M USD+39.8%—40.8%
NKTXNkarta, Inc.LTM Mar 2026-$99.93M USD+10.2%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.0%——
IMTXImmatics N.V.LTM Mar 2026-€215.35M EUR-1111.0%—577.4%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$221.78M USD+44.3%—58.5%
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.35M USD+23.6%—675.4%
IBRXImmunityBio, Inc.LTM Sep 2026-$1.11B USD-218.3%—607.9%
BNTXBioNTech SELTM Jun 2026-€1.64B EUR-321.6%—61.9%
MRNAModerna, Inc.LTM Sep 2026-$2.73B USD+13.4%—108.1%
Peer median (excluding IBRX) —+27.3%—60.2%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.